Orthofix Medical Inc

Orthofix Medical Inc (OFIX) Stock Analysis

$9.380

-0.205 (-2.19%)At close

Loading chart…
High
9.810
Open
9.640
VWAP
9.51
Volume
286.07K
Mkt Cap
505.89M
Low
9.335
Amount
2.72M
EV/EBITDA, TTM
5.12

Orthofix Medical Inc. is a global medical technology company. It offers a comprehensive portfolio of spinal hardware, bone growth therapies, limb reconstruction solutions, biologics and enabling technologies, including the 7D FLASH Navigation System. Its Global Spine segment offers two primary product categories: bone growth therapies and spinal implants, biologics, and enabling technologies. It provides implantable medical devices, biologics, enabling technologies, and other regenerative solutions which aim to restore the quality of life of patients suffering from diseases and traumas of the spine. It offers a variety of treatment solutions that incorporate multiple treatment modalities, such as mechanical, biological, and electromagnetic modes. Its Global Limb Reconstruction segment offers products and solutions for the underserved limb reconstruction market that encompasses four pillars: deformity correction, limb lengthening, complex fracture management, and limb preservation.

AI analysis of Orthofix Medical Inc (OFIX)

Hold

Orthofix Medical Inc is currently a hold. The stock is priced at $9.38, which is significantly below the analyst price targets of $13 and $14, indicating potential upside. However, the forward P/E ratio is extremely high at 500, suggesting that the stock may be overvalued based on future earnings expectations. Additionally, the company has reported a year-to-date change of -36.79% and a one-year change of -39.95%, reflecting significant declines in its stock price. The main risk is the company's ongoing net losses, with a net income of -$15.798 million in Q2 2026, which raises concerns about its financial stability and future profitability.

Analyst Ratings (7)

+127.40% upside
Buy
6 Buy
1 Hold
0 Sell
Current: 9.38
Low
18.00
Average
21.33
High
24.00

Canaccord

2026-08-10

Price Target

$13

Buy

Barrington

2026-08-06

Price Target

$14

Outperform

Stifel

2026-08-05

Price Target

$13

Buy

Stifel

2026-03-09

Price Target

$18

Buy

Canaccord

2026-02-26

Price Target

$20

Buy

Valuation Metrics

The current forward P/E ratio for Orthofix Medical Inc (OFIX) is 500.00, compared to its 5-year average forward P/E of 20.67.

Forward P/E

Strongly Overvalued
5Y Average P/E
20.67
Current P/E
500.00
Overvalued
192.72
Undervalued
-151.38

Forward EV/EBITDA

Undervalued
5Y Average EV/EBITDA
8.93
Current EV/EBITDA
5.12
Overvalued
11.73
Undervalued
6.13

Forward P/S

Undervalued
5Y Average P/S
0.78
Current P/S
0.44
Overvalued
1.04
Undervalued
0.51

Alphio AI Price Scenarios for OFIX

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%OFIX

$10.69

Scenario price

B

Base

Base · 50%OFIX

$10.56

Scenario price

B

Bear

Bear · 25%OFIX

$10.47

Scenario price

Whales holding OFIX

A

Armistice Capital LLC

+ HoldingOFIX

-8.20%

3M Return

Events Timeline

2026-08-05 (ET)

07:30:00

Orthofix Raises 2026 Net Sales Guidance to $845-$855 Million

07:30:00

Orthofix Reports Q2 Revenue of $210.9M, Beating Expectations

2026-07-06 (ET)

09:00:00

Nasdaq and S&P 500 Futures Rise as Chip Stocks Rebound

08:00:00

Orthofix Expects Medicare Reimbursement to Return to Pre-2026 Levels

2026-05-21 (ET)

10:00:00

Stock Down $2.38 to $9.77 in Morning Trading

News

OFIX FAQ — answered by Alphio AI

Orthofix Medical Inc. is a global medical technology company. It offers a comprehensive portfolio of spinal hardware, bone growth therapies, limb reconstruction solutions, biologics and enabling technologies, including the 7D FLASH Navigation System. Its Global Spine segment offers two primary product categories: bone growth therapies and spinal implants, biologics, and enabling technologies. It provides implantable medical devices, biologics, enabling technologies, and other regenerative solutions which aim to restore the quality of life of patients suffering from diseases and traumas of the spine. It offers a variety of treatment solutions that incorporate multiple treatment modalities, such as mechanical, biological, and electromagnetic modes. Its Global Limb Reconstruction segment offers products and solutions for the underserved limb reconstruction market that encompasses four pillars: deformity correction, limb lengthening, complex fracture management, and limb preservation. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Orthofix Medical Inc is currently a hold. The stock is priced at $9.38, which is significantly below the analyst price targets of $13 and $14, indicating potential upside. However, the forward P/E ratio is extremely high at 500, suggesting that the stock may be overvalued based on future earnings expectations. Additionally, the company has reported a year-to-date change of -36.79% and a one-year change of -39.95%, reflecting significant declines in its stock price. The main risk is the company's ongoing net losses, with a net income of -$15.798 million in Q2 2026, which raises concerns about its financial stability and future profitability.

7 analysts cover OFIX: 6 rate it Buy, 1 Hold and 0 Sell. The average price target is 21.33.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading